The immunotherapeutic vaccine candidate targets a toxic peptide called amyloid beta that is believed to damage the brain and trigger Alzheimer’s.
The FDA’s fast track program is designed to expedite the development and review of drugs intended to treat serious or life-threatening conditions.
Vaxxinity is slated to launch a phase 2B trial for the vaccine later this year, the company said in a May 2 press release.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
